alexa HIV-1 Broadly Neutralizing Antibodies: Identification,
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

HIV-1 Broadly Neutralizing Antibodies: Identification, Development and Vaccine Evaluation

Zaibao Zhang1,2*, Qian Guan3and Hongyu Yuan1,2

1Institute for Conservation and Utilization of Agro-bioresources in Dabie Mountains, Xinyang, Henan, China

2College of Life Science, Xinyang Normal College, Xinyang, Henan, China

3State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease and Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China

*Corresponding Author:
Zaibao Zhang
Institute for Conservation and Utilization of Agro-bioresources in Dabie Mountains
Xinyang, Henan, China
Tel: +86 13826272603
E-mail: [email protected]

Received date: November 02, 2016; Accepted date: November 12, 2016; Published date: November 19, 2016

Citation: Zhang Z, Guan Q, Yuan H (2016) HIV-1 Broadly Neutralizing Antibodies: Identification, Development and Vaccine Evaluation. J AIDS Clin Res 7:636. doi:10.4172/2155-6113.1000636

Copyright: © 2016 Zhang Z, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Numerous human immunodeficiency virus-1 (HIV-1) broadly neutralizing antibodies (bNAbs) have been produced and details of their generation, evolution and structure provide a blueprint for effective vaccination. Recent advances in next generation sequencing (NGS) technologies have allowed high-resolution characterization of the antibody repertoire, and have enabled thorough characterization of many HIV-1 bNAbs. These bNAbs identified conserved epitopes that may be used to design new vaccines and provided new tools for prophylaxis and therapy for HIV- 1 disease. In this review, we summarize the advance in HIV-1 bNAbs discovery, maturation and further describe emerging applications in vaccine design.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords